Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molibresib - GlaxoSmithKline

Drug Profile

Molibresib - GlaxoSmithKline

Alternative Names: GSK'762; GSK-525762; GSK525762A; GSK525762C; IBET762

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Amides; Antineoplastics; Benzodiazepines; Small molecules; Triazoles
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Carcinoma; Haematological malignancies; Prostate cancer; Solid tumours

Most Recent Events

  • 28 Jun 2023 Efficacy and adverse events data from a phase I/II trial in Breast cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 01 Mar 2022 GlaxoSmithKline terminates the phase II AMLM22/D1 trial for Acute myeloid leukaemia (In adults, In the elderly, In adolescents) in Australia (PO), due to termination of development of the candidate, prior to March 2022 (ACTRN12619000248167p)
  • 17 Feb 2022 Discontinued - Phase-I/II for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, South Korea, France, Canada, Australia, United Kingdom (PO) (GSK pipeline, February 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top